We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VEGF

News List

Patients Win When Support Is Personalized: New Study From Atlantis Healthcare Shows Treatment Persistence and Adherence Improved by 38% prnasia
March 08, 2021
Leading patient outcomes journal Patient Preference and Adherence has published a study that demonstrates significant improvement in treatment behaviors among patients with neovascular age-related macular degeneration (nAMD) who received personalized ...
EyePoint Announces First Patient Dosed in Trial of EYP-1901 for Wet AMD americanpharmaceuticalreview
February 03, 2021
EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).